CanSino mRNA vaccine nabs clinical trial approval from NMPA in China
Category: #health  By Pankaj Singh  Date: 2022-04-04
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

CanSino mRNA vaccine nabs clinical trial approval from NMPA in China

CanSino Biologics Inc. has reportedly announced that it received clinical trial approval from NMPA (National Medical Products Administration) for its COVID-19 mRNA vaccine in China.

Pre-clinical trial outcomes showcased that the COVID-19 mRNA vaccine of CanSinoBIO can persuade high-titer levels of neutralizing antibodies against multiple variants of SARS-CoV-2 VOC (variants of concern) recognized by the WHO (World Health Organization) which includes the most dominant strain and highly transmissible Omicron variant circulating in China and worldwide.

In addition, outcomes showcased that the mRNA vaccine of the company can persuade neutralizing antibodies with more cross-reactivity against VOCs worldwide and offer reinforced protection against infections caused due to the circulating variants in comparison to the original COVID-19 vaccines based on strains.

CanSinoBIO's application of the clinical trial for the COVID mRNA vaccine was filed by the parent firm and its division CanSino (Shanghai) Biotechnology Co. Ltd.

Established in July last year, CanSino Shanghai emphasizes developing a platform for mRNA technology and further reinforces the research and development capabilities of the company.

Compared with conventional vaccine tech platforms, the mRNA tech platform has substantial benefits in the production cycles and R&D process, comprising scalable, uniform, and fast production.

The company will continue to target the development of various innovative preventive vaccines in its assorted product pipeline with licensed technologies which includes Convidecia™, the COVID-19 vaccine’s inhaled version.

In December last year, the NMPA approved Menhycia™, CanSino’s MCV4 vaccine, making it the first vaccine to be approved in China.

For the unversed, CanSinoBIO dedicates to the production, research, and commercialization of inventive vaccines for global public health security.

It has 5 integrated platform technologies comprising synthetic vaccine technology, viral vector-based technology, mRNA technology, protein structure design and recombinant technology, and delivery and formulation technology.

Currently, it has established a strong pipeline of seventeen vaccines preventing twelve diseases.

Source credits:

https://www.prnewswire.com/news-releases/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china-301516328.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...